Recessive variants in ZNF142 cause a complex neurodevelopmental disorder with intellectual disability, speech impairment, seizures, and dystonia

Purpose

The purpose of this study was to expand the genetic architecture of neurodevelopmental disorders, and to characterize the clinical features of a novel cohort of affected individuals with variants in ZNF142, a C2H2domain-containing transcription factor.

Methods

Four independent research centers used exome sequencing to elucidate the genetic basis of neurodevelopmental phenotypes in four unrelated families. Following bioinformatic filtering, query of control data sets, and secondary variant confirmation, we aggregated findings using an online data sharing platform. We performed in-depth clinical phenotyping in all affected individuals.

Results

We identified seven affected females in four pedigrees with likely pathogenic variants in ZNF142 that segregate with recessive disease. Affected cases in three families harbor either nonsense or frameshifting likely pathogenic variants predicted to undergo nonsense mediated decay. One additional trio bears ultrarare missense variants in conserved regions of ZNF142 that are predicted to be damaging to protein function. We performed clinical comparisons across our cohort and noted consistent presence of intellectual disability and speech impairment, with variable manifestation of seizures, tremor, and dystonia.

Conclusion

Our aggregate data support a role for ZNF142 in nervous system development and add to the emergent list of zinc finger proteins that contribute to neurocognitive disorders.

 

Click here for more details.

Related Post

  • Posted on 14 October, 2024
    Redenlab is pleased to announce that Dr. Adam Vogel, an expert in speech and language function, will be presenting at...
    • Posted on 4 September, 2024
      Dr. Adam Vogel, CSO of Redenlab, will be speaking alongside Dr. Tairmae Kangarloo, Associate Director of Digital Strategy at Takeda,...
      • Posted on 3 September, 2024
        Redenlab is proud to announce our participation in the 14th International Conference on Frontotemporal Dementias (ICFTD), to be held in...